Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 28 entries
Sorted by: Best Match Show Resources per page
Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting-factor concentrates considered safe against human immunodeficiency and hepatitis C viruses.

Haemophilia : the official journal of the World Federation of Hemophilia

Flores G, Juárez JC, Montoro JB, Tusell JM, Altisent C, Juste C, Jardí R.
PMID: 27214319
Haemophilia. 1995 Apr;1(2):115-7. doi: 10.1111/j.1365-2516.1995.tb00050.x.

Clotting-factor concentrates (CFC) are a potential source of transmission of blood-borne viruses. Newer physical and chemical methods (pasteurization, wet-heating, solvent/detergent treating) developed to inactivate viruses are effective against HIV, HBV and HCV. However, it is not clear if these...

Cite
Flores G, Juárez JC, Montoro JB, et al. Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting-factor concentrates considered safe against human immunodeficiency and hepatitis C viruses. Haemophilia. 1995;1(2):115-7doi: 10.1111/j.1365-2516.1995.tb00050.x.
Flores, G., Juárez, J. C., Montoro, J. B., Tusell, J. M., Altisent, C., Juste, C., & Jardí, R. (1995). Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting-factor concentrates considered safe against human immunodeficiency and hepatitis C viruses. Haemophilia : the official journal of the World Federation of Hemophilia, 1(2), 115-7. https://doi.org/10.1111/j.1365-2516.1995.tb00050.x
Flores, G, et al. "Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting-factor concentrates considered safe against human immunodeficiency and hepatitis C viruses." Haemophilia : the official journal of the World Federation of Hemophilia vol. 1,2 (1995): 115-7. doi: https://doi.org/10.1111/j.1365-2516.1995.tb00050.x
Flores G, Juárez JC, Montoro JB, Tusell JM, Altisent C, Juste C, Jardí R. Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting-factor concentrates considered safe against human immunodeficiency and hepatitis C viruses. Haemophilia. 1995 Apr;1(2):115-7. doi: 10.1111/j.1365-2516.1995.tb00050.x. PMID: 27214319.
Copy Download .nbib Format: NLM
Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism.

Hematology. American Society of Hematology. Education Program

Ansell JE, Weitz JI, Comerota AJ.
PMID: 11701546
Hematology Am Soc Hematol Educ Program. 2000;266-284. doi: 10.1182/asheducation-2000.1.266.

This review focuses on antithrombotic therapy for venous thromboembolism and covers a diverse range of topics including a discussion of emerging anticoagulant drugs, a renewed focus on thrombolytic agents for selected patients, and an analysis of the factors leading...

Cite
Ansell JE, Weitz JI, Comerota AJ. Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. Hematology Am Soc Hematol Educ Program. 2000;266-284doi: 10.1182/asheducation-2000.1.266.
Ansell, J. E., Weitz, J. I., & Comerota, A. J. (2000). Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. Hematology. American Society of Hematology. Education Program, 266-284. https://doi.org/10.1182/asheducation-2000.1.266
Ansell, Jack E., et al. "Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism." Hematology. American Society of Hematology. Education Program vol. (2000): 266-284. doi: https://doi.org/10.1182/asheducation-2000.1.266
Ansell JE, Weitz JI, Comerota AJ. Advances in Therapy and the Management of Antithrombotic Drugs for Venous Thromboembolism. Hematology Am Soc Hematol Educ Program. 2000;266-284. doi: 10.1182/asheducation-2000.1.266. PMID: 11701546.
Copy Download .nbib Format: NLM
Advances in the Monitoring of Oral Anticoagulation: Point-of-Care Testing, Patient Self-Monitoring, and Patient Self-Management.

Journal of thrombosis and thrombolysis

Leaning KE, Ansell JE.
PMID: 10602567
J Thromb Thrombolysis. 1996;3(4):377-383. doi: 10.1007/BF00133081.

Oral anticoagulation with warfarin sodium has proven to be an effective therapy for patients at risk for thromboembolic disease, but due to its high risk/benefit ratio, many physicians are reluctant to prescribe the drug. The development of capillary whole-blood...

Cite
Leaning KE, Ansell JE. Advances in the Monitoring of Oral Anticoagulation: Point-of-Care Testing, Patient Self-Monitoring, and Patient Self-Management. J Thromb Thrombolysis. 1996;3(4):377-383doi: 10.1007/BF00133081.
Leaning, K. E., & Ansell, J. E. (1996). Advances in the Monitoring of Oral Anticoagulation: Point-of-Care Testing, Patient Self-Monitoring, and Patient Self-Management. Journal of thrombosis and thrombolysis, 3(4), 377-383. https://doi.org/10.1007/BF00133081
Leaning, and Ansell. "Advances in the Monitoring of Oral Anticoagulation: Point-of-Care Testing, Patient Self-Monitoring, and Patient Self-Management." Journal of thrombosis and thrombolysis vol. 3,4 (1996): 377-383. doi: https://doi.org/10.1007/BF00133081
Leaning KE, Ansell JE. Advances in the Monitoring of Oral Anticoagulation: Point-of-Care Testing, Patient Self-Monitoring, and Patient Self-Management. J Thromb Thrombolysis. 1996;3(4):377-383. doi: 10.1007/BF00133081. PMID: 10602567.
Copy Download .nbib Format: NLM
High Monocyte Count and Expression of .

Cancers

Åberg AM, Bergström SH, Thysell E, Tjon-Kon-Fat LA, Nilsson JA, Widmark A, Thellenberg-Karlsson C, Bergh A, Wikström P, Lundholm M.
PMID: 34067757
Cancers (Basel). 2021 May 17;13(10). doi: 10.3390/cancers13102424.

Increasing evidence indicates calcium-binding S100 protein involvement in inflammation and tumor progression. In this prospective study, we evaluated the mRNA levels of two members of this family,

Cite
Åberg AM, Bergström SH, Thysell E, et al. High Monocyte Count and Expression of . Cancers (Basel). 2021;13(10)doi: 10.3390/cancers13102424.
Åberg, A. M., Bergström, S. H., Thysell, E., Tjon-Kon-Fat, L. A., Nilsson, J. A., Widmark, A., Thellenberg-Karlsson, C., Bergh, A., Wikström, P., & Lundholm, M. (2021). High Monocyte Count and Expression of . Cancers, 13(10), . https://doi.org/10.3390/cancers13102424
Åberg, Anna-Maja, et al. "High Monocyte Count and Expression of ." Cancers vol. 13,10 (2021). doi: https://doi.org/10.3390/cancers13102424
Åberg AM, Bergström SH, Thysell E, Tjon-Kon-Fat LA, Nilsson JA, Widmark A, Thellenberg-Karlsson C, Bergh A, Wikström P, Lundholm M. High Monocyte Count and Expression of . Cancers (Basel). 2021 May 17;13(10). doi: 10.3390/cancers13102424. PMID: 34067757; PMCID: PMC8156049.
Copy Download .nbib Format: NLM
Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C.

Molecular oncology

Thysell E, Köhn L, Semenas J, Järemo H, Freyhult E, Lundholm M, Thellenberg Karlsson C, Damber JE, Widmark A, Crnalic S, Josefsson A, Welén K, Nilsson RJA, Bergh A, Wikström P.
PMID: 34889043
Mol Oncol. 2021 Dec 10; doi: 10.1002/1878-0261.13158. Epub 2021 Dec 10.

To improve treatment of metastatic prostate cancer, the biology of metastases needs to be understood. We recently described three subtypes of prostate cancer bone metastases (MetA-C), based on differential gene expression. The aim of this study was to verify...

Cite
Thysell E, Köhn L, Semenas J, et al. Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C. Mol Oncol. 2021;doi: 10.1002/1878-0261.13158.
Thysell, E., Köhn, L., Semenas, J., Järemo, H., Freyhult, E., Lundholm, M., Thellenberg Karlsson, C., Damber, J. E., Widmark, A., Crnalic, S., Josefsson, A., Welén, K., Nilsson, R. J. A., Bergh, A., & Wikström, P. (2021). Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C. Molecular oncology, . https://doi.org/10.1002/1878-0261.13158
Thysell, Elin, et al. "Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C." Molecular oncology vol. (2021). doi: https://doi.org/10.1002/1878-0261.13158
Thysell E, Köhn L, Semenas J, Järemo H, Freyhult E, Lundholm M, Thellenberg Karlsson C, Damber JE, Widmark A, Crnalic S, Josefsson A, Welén K, Nilsson RJA, Bergh A, Wikström P. Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C. Mol Oncol. 2021 Dec 10; doi: 10.1002/1878-0261.13158. Epub 2021 Dec 10. PMID: 34889043.
Copy Download .nbib Format: NLM
Preface.

Journal of thrombosis and thrombolysis

Ansell JE.
PMID: 10767125
J Thromb Thrombolysis. 1998 Jan;5(3):5. doi: 10.1023/a:1013253601022.

No abstract available.

Cite
Ansell JE. Preface. J Thromb Thrombolysis. 1998;5(3):5doi: 10.1023/a:1013253601022.
Ansell, J. E. (1998). Preface. Journal of thrombosis and thrombolysis, 5(3), 5. https://doi.org/10.1023/a:1013253601022
Ansell. "Preface." Journal of thrombosis and thrombolysis vol. 5,3 (1998): 5. doi: https://doi.org/10.1023/a:1013253601022
Ansell JE. Preface. J Thromb Thrombolysis. 1998 Jan;5(3):5. doi: 10.1023/a:1013253601022. PMID: 10767125.
Copy Download .nbib Format: NLM
A Systems Approach to Prostate Cancer Classification-Letter.

Cancer research

Thysell E, Ylitalo EB, Jernberg E, Bergh A, Wikström P.
PMID: 29212852
Cancer Res. 2017 Dec 15;77(24):7131-7132. doi: 10.1158/0008-5472.CAN-16-3231. Epub 2017 Dec 06.

No abstract available.

Cite
Thysell E, Ylitalo EB, Jernberg E, et al. A Systems Approach to Prostate Cancer Classification-Letter. Cancer Res. 2017;77(24):7131-7132doi: 10.1158/0008-5472.CAN-16-3231.
Thysell, E., Ylitalo, E. B., Jernberg, E., Bergh, A., & Wikström, P. (2017). A Systems Approach to Prostate Cancer Classification-Letter. Cancer research, 77(24), 7131-7132. https://doi.org/10.1158/0008-5472.CAN-16-3231
Thysell, Elin, et al. "A Systems Approach to Prostate Cancer Classification-Letter." Cancer research vol. 77,24 (2017): 7131-7132. doi: https://doi.org/10.1158/0008-5472.CAN-16-3231
Thysell E, Ylitalo EB, Jernberg E, Bergh A, Wikström P. A Systems Approach to Prostate Cancer Classification-Letter. Cancer Res. 2017 Dec 15;77(24):7131-7132. doi: 10.1158/0008-5472.CAN-16-3231. Epub 2017 Dec 06. PMID: 29212852.
Copy Download .nbib Format: NLM
A multivariate approach to investigate docking parameters' effects on docking performance.

Journal of chemical information and modeling

Andersson CD, Thysell E, Lindström A, Bylesjö M, Raubacher F, Linusson A.
PMID: 17559207
J Chem Inf Model. 2007 Jul-Aug;47(4):1673-87. doi: 10.1021/ci6005596. Epub 2007 Jun 09.

Increasingly powerful docking programs for analyzing and estimating the strength of protein-ligand interactions have been developed in recent decades, and they are now valuable tools in drug discovery. Software used to perform dockings relies on a number of parameters...

Cite
Andersson CD, Thysell E, Lindström A, et al. A multivariate approach to investigate docking parameters' effects on docking performance. J Chem Inf Model. 2007;47(4):1673-87doi: 10.1021/ci6005596.
Andersson, C. D., Thysell, E., Lindström, A., Bylesjö, M., Raubacher, F., & Linusson, A. (2007). A multivariate approach to investigate docking parameters' effects on docking performance. Journal of chemical information and modeling, 47(4), 1673-87. https://doi.org/10.1021/ci6005596
Andersson, C David, et al. "A multivariate approach to investigate docking parameters' effects on docking performance." Journal of chemical information and modeling vol. 47,4 (2007): 1673-87. doi: https://doi.org/10.1021/ci6005596
Andersson CD, Thysell E, Lindström A, Bylesjö M, Raubacher F, Linusson A. A multivariate approach to investigate docking parameters' effects on docking performance. J Chem Inf Model. 2007 Jul-Aug;47(4):1673-87. doi: 10.1021/ci6005596. Epub 2007 Jun 09. PMID: 17559207.
Copy Download .nbib Format: NLM
Efficacy of high-temperature dry heat in inactivating parvovirus.

Haemophilia : the official journal of the World Federation of Hemophilia

Rubinstein DB, Flores G, Juarez JC, Montoro JB, Tusell JM, Altisent C.
PMID: 27213912
Haemophilia. 1996 Jan;2(1):64. doi: 10.1111/j.1365-2516.1996.tb00016.x.

No abstract available.

Cite
Rubinstein DB, Flores G, Juarez JC, et al. Efficacy of high-temperature dry heat in inactivating parvovirus. Haemophilia. 1996;2(1):64doi: 10.1111/j.1365-2516.1996.tb00016.x.
Rubinstein, D. B., Flores, G., Juarez, J. C., Montoro, J. B., Tusell, J. M., & Altisent, C. (1996). Efficacy of high-temperature dry heat in inactivating parvovirus. Haemophilia : the official journal of the World Federation of Hemophilia, 2(1), 64. https://doi.org/10.1111/j.1365-2516.1996.tb00016.x
Rubinstein, D B, et al. "Efficacy of high-temperature dry heat in inactivating parvovirus." Haemophilia : the official journal of the World Federation of Hemophilia vol. 2,1 (1996): 64. doi: https://doi.org/10.1111/j.1365-2516.1996.tb00016.x
Rubinstein DB, Flores G, Juarez JC, Montoro JB, Tusell JM, Altisent C. Efficacy of high-temperature dry heat in inactivating parvovirus. Haemophilia. 1996 Jan;2(1):64. doi: 10.1111/j.1365-2516.1996.tb00016.x. PMID: 27213912.
Copy Download .nbib Format: NLM
Autoimmune diseases of the brain, imaging and clinical review.

The neuroradiology journal

Shadmani G, Simkins TJ, Assadsangabi R, Apperson M, Hacein-Bey L, Raslan O, Ivanovic V.
PMID: 34490814
Neuroradiol J. 2021 Sep 07;19714009211042879. doi: 10.1177/19714009211042879. Epub 2021 Sep 07.

There is an extensive spectrum of autoimmune entities that can involve the central nervous system, which has expanded with the emergence of new imaging modalities and several clinicopathologic entities. Clinical presentation is usually non-specific, and imaging has a critical...

Cite
Shadmani G, Simkins TJ, Assadsangabi R, et al. Autoimmune diseases of the brain, imaging and clinical review. Neuroradiol J. 2021;19714009211042879doi: 10.1177/19714009211042879.
Shadmani, G., Simkins, T. J., Assadsangabi, R., Apperson, M., Hacein-Bey, L., Raslan, O., & Ivanovic, V. (2021). Autoimmune diseases of the brain, imaging and clinical review. The neuroradiology journal, 19714009211042879. https://doi.org/10.1177/19714009211042879
Shadmani, Ghazal, et al. "Autoimmune diseases of the brain, imaging and clinical review." The neuroradiology journal vol. (2021): 19714009211042879. doi: https://doi.org/10.1177/19714009211042879
Shadmani G, Simkins TJ, Assadsangabi R, Apperson M, Hacein-Bey L, Raslan O, Ivanovic V. Autoimmune diseases of the brain, imaging and clinical review. Neuroradiol J. 2021 Sep 07;19714009211042879. doi: 10.1177/19714009211042879. Epub 2021 Sep 07. PMID: 34490814.
Copy Download .nbib Format: NLM
Hypersecretory Paraganglioma Presenting as Acute Aortic Dissection.

JACC. Case reports

Lorenzo CJ, Abdelal QK, Conte JI, Villasmil RJ, Wiese-Rometsch W, Sell JE.
PMID: 34317007
JACC Case Rep. 2020 Aug 19;2(10):1510-1514. doi: 10.1016/j.jaccas.2020.05.097. eCollection 2020 Aug.

Abrupt, transient, and severe hypertension evoked by catecholamine-secreting tumors has the potential to manifest as acute aortic dissection. We report the successful, multidisciplinary management of an insidious, extra-adrenal, functional paraganglioma, suddenly presenting as acute aortic dissection. (

Cite
Lorenzo CJ, Abdelal QK, Conte JI, et al. Hypersecretory Paraganglioma Presenting as Acute Aortic Dissection. JACC Case Rep. 2020;2(10):1510-1514doi: 10.1016/j.jaccas.2020.05.097.
Lorenzo, C. J., Abdelal, Q. K., Conte, J. I., Villasmil, R. J., Wiese-Rometsch, W., & Sell, J. E. (2020). Hypersecretory Paraganglioma Presenting as Acute Aortic Dissection. JACC. Case reports, 2(10), 1510-1514. https://doi.org/10.1016/j.jaccas.2020.05.097
Lorenzo, Christian J, et al. "Hypersecretory Paraganglioma Presenting as Acute Aortic Dissection." JACC. Case reports vol. 2,10 (2020): 1510-1514. doi: https://doi.org/10.1016/j.jaccas.2020.05.097
Lorenzo CJ, Abdelal QK, Conte JI, Villasmil RJ, Wiese-Rometsch W, Sell JE. Hypersecretory Paraganglioma Presenting as Acute Aortic Dissection. JACC Case Rep. 2020 Aug 19;2(10):1510-1514. doi: 10.1016/j.jaccas.2020.05.097. eCollection 2020 Aug. PMID: 34317007; PMCID: PMC8302177.
Copy Download .nbib Format: NLM
A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer.

Clinical epigenetics

Ylitalo EB, Thysell E, Landfors M, Brattsand M, Jernberg E, Crnalic S, Widmark A, Hultdin M, Bergh A, Degerman S, Wikström P.
PMID: 34193246
Clin Epigenetics. 2021 Jun 30;13(1):133. doi: 10.1186/s13148-021-01119-0.

BACKGROUND: Patients with metastatic prostate cancer (PC) are treated with androgen deprivation therapy (ADT) that initially reduces metastasis growth, but after some time lethal castration-resistant PC (CRPC) develops. A better understanding of the tumor biology in bone metastases is...

Cite
Ylitalo EB, Thysell E, Landfors M, et al. A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer. Clin Epigenetics. 2021;13(1):133doi: 10.1186/s13148-021-01119-0.
Ylitalo, E. B., Thysell, E., Landfors, M., Brattsand, M., Jernberg, E., Crnalic, S., Widmark, A., Hultdin, M., Bergh, A., Degerman, S., & Wikström, P. (2021). A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer. Clinical epigenetics, 13(1), 133. https://doi.org/10.1186/s13148-021-01119-0
Ylitalo, Erik Bovinder, et al. "A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer." Clinical epigenetics vol. 13,1 (2021): 133. doi: https://doi.org/10.1186/s13148-021-01119-0
Ylitalo EB, Thysell E, Landfors M, Brattsand M, Jernberg E, Crnalic S, Widmark A, Hultdin M, Bergh A, Degerman S, Wikström P. A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer. Clin Epigenetics. 2021 Jun 30;13(1):133. doi: 10.1186/s13148-021-01119-0. PMID: 34193246; PMCID: PMC8244194.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 28 entries